Markets:

Overview

News

Currencies

International

Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

28.00 +1.21 (+4.52%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 08, 2023

Via Benzinga

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

March 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results

February 28, 2023

From Castle Biosciences, Inc.

Via Business Wire

Looking Into Castle Biosciences's Return On Capital Employed ↗

November 16, 2022

Via Benzinga

Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

February 24, 2023

From Castle Biosciences, Inc.

Via Business Wire

Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

February 22, 2023

From Castle Biosciences, Inc.

Via Business Wire

Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines

February 09, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

February 07, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

February 01, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023

January 23, 2023

From Castle Biosciences, Inc.

Via Business Wire

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

January 17, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

January 08, 2023

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

November 21, 2022

From Castle Biosciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

November 17, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

November 15, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

November 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts ↗

November 07, 2022

Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes...

Via Benzinga

This Analyst With 82% Accuracy Rate Boosts PT On Booking Holdings; Here Are 5 Stock Picks For Thursday From Benzinga's Most Accurate Analysts ↗

November 04, 2022

Via Benzinga

Castle Biosciences Announces Third Quarter 2022 Results

November 02, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at Upcoming Investor Conferences

November 01, 2022

From Castle Biosciences, Inc.

Via Business Wire

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

October 31, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

October 27, 2022

From Castle Biosciences, Inc.

Via Business Wire

New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone

October 25, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

October 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure

October 20, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

October 19, 2022

From Castle Biosciences, Inc.

Via Business Wire

Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

October 13, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

October 11, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

October 10, 2022

From Castle Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.